NCT00838487Unknown3 期
Phase 3 Study, to Evaluate Safety & Efficacy of the Association Condroflex + Therapeutic Exercises Compared to Placebo + Therapeutic Exercises, in Subjects With Knee OA
Zodiac Produtos Farmaceuticos S.A.1 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2009年3月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- improvement of pain
研究概览
简要总结
Primary Objective: To compare, after 12 weeks of double-blind treatment, the evolution of the improvement of pain (at rest and during / after exercise) in the questionnaire WOMAC (Western Ontario and McMaster Universities Arthritis Index), achieved with Condroflex ® oral administration(sulfate glucosamine + chondroitin sulfate sodium) in association with therapeutic exercises, compared to placebo in association with therapeutic exercises in individuals with knee OA and not exposed to prior treatment with the products under investigation.
详细描述
To have osteoarthritis degree 2 or 3 / To be capable to consent
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •to have knee osteoarthritis degree 2 or 3
- •to be capable to consent
排除标准
- •previous drug treatment
- •concomitant diseases
- •concomitant drugs
结局指标
主要结局
improvement of pain
时间窗: 12 week
次要结局
- rigidity restriction(12 week)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)Rheumatoid ArthritisNCT02706951AbbVie648
已完成
3 期
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled AsthmaUncontrolled AsthmaNCT02161757AstraZeneca1,207
已完成
3 期
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled AsthmaUncontrolled AsthmaNCT02194699AstraZeneca856
已完成
3 期
A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)Rheumatoid Arthritis (RA)NCT02955212AbbVie338
已完成
3 期
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer TherapyCancer Therapy-Related DiarrheaChemotherapy-related DiarrheaAdult Solid TumorProphylaxis of DiarrheaSymptomatic Relief of DiarrheaTargeted Therapy-related DiarrheaNCT04538625Napo Pharmaceuticals, Inc.287